NYU Langone Health, in partnership with the National Heart, Lung, and Blood Institute (NHLBI), has announced the development of a groundbreaking clinical tool aimed at improving pulmonary embolism (PE) risk assessment. This tool integrates advanced clinical decision support (CDS) features alongside behavioral nudges to guide provider decision-making efficiently. Expected to bridge existing gaps in PE diagnosis, this innovation is set to influence clinical workflows across multiple electronic health record (EHR) systems.
What changed?
The research team is set to introduce a new PE risk prediction tool that operates independent of specific EHR platforms. While many clinical tools depend on direct integration with proprietary systems, this one is designed to be universally adaptable. It incorporates behavioral nudges, a form of gentle persuasion reinforced by data-driven insights, to encourage greater adoption among providers. As of November 2025, this tool is classified under the “Not yet recruiting” stage.
How does the tool work?
The CDS tool functions by analyzing patient data, applying predictive analytics to estimate the probability of PE, and presenting evidence-based recommendations to clinicians. Behavioral nudges are embedded within the interface to prompt action and reduce cognitive bias during decision-making processes. This agnostic design allows for seamless integration into multiple healthcare infrastructure systems without dependence on specific EHR software.
Key Features:
- Risk prediction model validated by clinical research.
- User-friendly interface with simplified decision prompts.
- Compatibility across diverse technological platforms.
Who is affected?
This development primarily targets hospital systems, clinicians, and regulatory teams overseeing patient safety initiatives. Providers encountering cases of suspected or confirmed PE can leverage this tool to enhance diagnostic accuracy. Clinical teams in environments with variable EHR systems may find its agnostic compatibility especially beneficial for cross-platform communication.
FAQs
- What condition does the tool address?
The tool is designed to improve assessments of pulmonary embolism risks. - Is this tool available for immediate use?
No, as of November 2025, it is listed as “Not yet recruiting.” - Does the tool integrate with specific EHR systems?
No, the tool is EHR-agnostic, meaning it can function across different platforms. - Who developed the tool?
The tool is a joint initiative by NYU Langone Health and the NHLBI.
Conclusion
The launch of this pulmonary embolism risk prediction tool signals a transformative step towards harmonizing technology and behavioral science to improve diagnostic reliability. Providers and affiliated regulatory teams should closely monitor developments, implementation plans, and trial outcomes as this promising tool advances toward clinical use.
Disclaimer
This article is provided for informational purposes only. It does not constitute legal or clinical advice. Readers should consult regulatory guidance and institutional policies for specific applications.
Announcement and link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07249385?term=medical+device